View
2
Download
0
Category
Preview:
Citation preview
Click to edit Master title style
Corporate Presentation
June 2019
2
65%10%
25%
Legacy Revenue
Consumables
Instruments
Diagnostics
B U S I N E S S O V E R V I E W C O R P O R A T E
Business Overview
At a Glance:
President and CEO: Chuck KummethHeadquarters: Minneapolis, MNNumber of Employees: ~2,100World Wide Presence: 35 Locations FY2018 Revenues: $643 millionNASDAQ: TECHMarket Cap: ~$7B
3
B U S I N E S S O V E R V I E W C O R P O R A T E
25%
37%
15%
23%
Academia
Pharma/Biotech
Distributors
OEM
$643MM
Revenue by Customer Type
4
B U S I N E S S O V E R V I E W C O R P O R A T E
57%
28%
15%
AmericasEMEAAsia
$643MM
Revenue by Geography
5
Pl
Top Strategies
Geographic ExpansionCore Product
Innovation
Culture Creation & Talent
Gap Filling M&A and Market Expansion
6
Pre-FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019
Rev
enu
e ($
mill
ion
)
Org
anic
Gro
wth
(%
)
Disciplined M&A and Investment Strategy to Impact Growth
311358
452499
563643
522
0
5
10
15
0
200
400
600
800
FY13 FY14 FY15 FY16 FY17 FY18 FY19-9mo
7
~15%
Reagent Solutions
Diagnostics
Develop and manufactures biological reagents used in all aspects of life science research
Develops and manufactures controls, calibrators and diagnostic assays for the regulated diagnostic market
Manual and automated protein analysis solutions that improve the efficiency of process work streams & quantitate secreted proteins
GenomicsAdvanced, tissue morphology friendly RNA in situhybridization (ISH) assay for transcriptome analysis & prostate cancer molecular diagnostic
Analytical Solutions
Our New Segment Structure
Protein Sciences Segent
Diagnostics and Genomics Segment
Protein Sciences Segment
8
Serving All Aspects of Life Science
Basic Research
Applied Research
Life Science Tools
InstrumentsReagents Consumables
DiagnosticsClinical
ResearchPharma
Production
Pharma Development
Ap
plicatio
ns &
Markets
Pro
du
cts
9
Click to edit Master title style
Protein Sciences Segment
1 0
Proteins: High Value & High Growth Applications
Specialty MediaSupplements
Cell Therapy(GMP grade Proteins)
Proteins
Cancer Immunotherapy Research(Immune Checkpoint Proteins)
Bioprocessing(Growth Factors for large
scale Production)
1 1
Immunocytochemistry
Luminex® Assays
ArraysEllaTM
ELISA Assays
Blocking/NeutralizationAssays
Western Blot and Simple Western
Immunohistochemistry
Flow Cytometry
Antibodies: High Quality Reagents Drives Versatility in Applications
1 2
Current Areas of Growth
Epigenetics
Stem CellsCancer Research
Neurodegeneration
Small Molecules: Research Area Emphasis
Functions
Inhibitors
Activators
Agonists
Antagonists
Blockers
Modulators
Ligands
GMP Grade Reagents
1 3
Fully Validated
Manual
HomemadeAssays
Fully Automated
DuoSet®
FluorChemAlphaImager Single-Cell
Arrays Luminex®
Quantikine® Simple Plex ™
Simple Western™
Immunoassays: Different Users & Different Needs
1 4
Separation
Imaging
Analysis
Microfluidics
Immunoassay
Measurement
Proteins have complex structures
Analytical Solutions Division
14
1 5
Immune Cell Therapy Opportunities
Profiling CAR activity via
ACD technology
GMP Proteins
Assay/Ab platformsfor QC
Ella for CRSDetection/monitoring
Abs for T-Cell Activation using
QUAD Technologies
1 6
QuickGel™ Microparticles for Cell Therapy Applications
Only releasable, non-magnetic cell selection technology
Bringing automation and GMP-compliance to our magnetic bead-free cell separation
Revolutionizing the clinical workflow
Current RUO cell selection solution
Directly-conjugated antibodies
1 7
Click to edit Master title style
Diagnostics & Genomics Segment
1 8
Devens, MA
Devens, MA
Waltham, MA
Rennes, France
Milan, Italy
Newark, CA
Emeryville, CA
San Marcos, CA
Minneapolis, MN
Beijing, China
Diagnostics Genomics
Munich, Germany
Locations & Brands in Bio-Techne’s Diagnostics and Genomics Segment
1 9
• Point of Care
• Laboratory instrumentation
Biological components & Tests
• Cardiac Markers
• Lipids
• Specific Proteins
• Cancer Markers
• Toxicology
• TDM
• DOA
Instrument companiesCalibration and control products
• General Chemistry
• Hematology
• Diabetes (Blood glucose, HbA1c)
• Blood Gas/Electrolytes
• Immunochemistry
• Urine Chemistry/Urinalysis
• Coagulation
Diagnostics Division Overview
2 0
Genomics Division Overview: RNAscope - In-Situ Hybridization (RNA-ISH)
• Advanced Cell Diagnostics
• Technology allows both manual and automated gene expression analysis
• Optimized for single and multiplex analysis
• >25,000 off-the-shelf target probes
• RNAscope and BaseScope are current assays on the market
• Pharma Assay Services further deploys the technology to select customers
• Represents the most advanced RNA in situ hybridization (ISH) assay for
transcriptome analysis and gene quantitation while retaining tissue morphology
RNAscope® 2012
DNAFISH 1990s
RNA
ProteinIHC 1970s
RNAscope VENTANA LEICA
2 1
RNAscope Improvements: HiPlex Detection of 12 Neuronal Markers in Mouse Brain
Round 2 Round 2 Round 3DAPI images from Round 1-4
Image Registration
Select targetsSelect Pseudo colorSave composite
2 2
Key Properties
Frequency
Ability to Enrich or Select
Quality of Isolated Nucleic Acids
CTCs
Infrequent in early stages of disease
Yes
Good
cfDNA
Difficult to find within “noise” of
contaminating DNA
No
Poor due to enzymes exposure
Exosomes
Abundant
Yes
High quality-shielded
Liquid Biopsies: CTCs, cfDNA & Exosomes
2 3
The EPI Test
The EPITM risk score is used to risk stratify likelihood of high grade (GS > 7) prostate cancer on initial biopsy in men 50-years and older, with a PSA 2-10ng/mL.
The Workflow:
Intended Use:
Inclusion of EPI in 2019 NCCN Guidelines (Jan 2019)
2 4
Healthy Pipeline of Future Products for Different Markets and Applications Drive Growth
Commercial Channels UROLOGY NEPHROLOGY NEUROLOGY MEDICAL ONCOLOGY
PROSTATE CANCER BLADDER CANCER KIDNEY TX DEGENERATIVE, MENTAL
DISORDER
DETECTION Develop PSA ReplacementAlzheimer’s, Parkinson’s,
Other CDxScreening Panel, CDx
DIAGNOSISAlzheimer’s, Parkinson’s,
Other CDx
PROGNOSIS EPI Bladder Signature Breast Ca, Other CDx
TREATMENT SELECTION
EPI, EPI AS, ARv7, Other CDx
Bladder Signature Kidney SignatureAlzheimer’s, Parkinson’s,
Other CDx
Lung Ca Panel,EGFR/T790M, EGFRv3,
BRAF, 170 Gene Panel, CDx
PATIENT & TREATMENT
MONITORING
EPI AS, EPI TM, ARv7, Other CDx
Bladder Signature Kidney SignatureAlzheimer’s, Parkinson’s,
Other CDx
Lung Ca Panel,EGFR/T790M, EGFRv3,
BRAF, 170 Gene Panel, CDx
Ap
plic
atio
ns
Commercial Channels
2 5
Our Long Term Strategic Portfolio
ACD – Tissue Biopsy
Cell Culture/Therapy
Core Products
Instruments – Protein Analysis
Exosomes Dx – Liquid Biopsy
Bio-Techne Abs
2 6
Rev CAGR• Analytical Solutions +15-20%• Reagent Solutions +5-7%
Protein Sciences Segment +8-11%
• Diagnostics +4-6%• Genomics -- ACD +20-30%• Genomics – ExoDx ~ $150mm
Diagnostics & Genomics Segment ~ +20%
~$1.2B
As we look forward, our financial goals get larger
Revenue
FY13 FY16 FY18 FY23 FY13 FY16 FY18 FY23
~$0.5B
~40%OM
Adj. Operating Income
* All figures are expressed in millions.** Assumes no further unannounced acquisitions
OM% in 5yrs• Analytical Solutions ~ 30%• Reagent Solutions +50%
Protein Sciences Segment mid 40s%
• Diagnostics ~ 30%• Genomics -- ACD mid 30s%• Genomics – ExoDx ~ 30%
Diagnostics & Genomics Segment low 30s%
2 7
~1800
>300,000Products
~2,100Employees
>40Years
>500,000Citations
Our brands bring you >300,000 quality products
Nearly 2,100 employees globally
Our companies have been manufacturing and sourcing reagents for more than 40 years
Generated using our products
6 instrument platforms that leverage biological content
6Platforms
Global Footprint
North America, Europe, and Asia
Recommended